» Authors » Mohammed F Aldawsari

Mohammed F Aldawsari

Explore the profile of Mohammed F Aldawsari including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 72
Citations 499
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Abla K, Alamoudi M, Soliman G, Abdel-Kader M, Aldawsari M, Mehanna M
Int J Nanomedicine . 2025 Jan; 20():605-624. PMID: 39835177
Introduction: Androgenetic alopecia (AGA) is a multifactorial and age-related dermatological disease that affects both males and females, usually at older ages. Traditional hair repair drugs exemplified by minoxidil have limitations...
2.
Gomaa M, Ahmed A, El Rayes S, Ali I, Fathalla W, Alturki M, et al.
RSC Adv . 2024 Nov; 14(48):35679-35695. PMID: 39524090
We have designed 17 new 2-oxo-3-phenylquinoxalines the chemoselective Michael reaction of 3-phenylquinoxalin-2(1)-one with acrylic acid derivatives. The ester, ethyl 3-(2-oxo-3-phenylquinoxalin-1(2)-yl)propanoate, was reacted with hydroxylamine and hydrazine to produce -hydroxy-3-(2-oxo-3-phenylquinoxalin-1(2)-yl)propanamide and...
3.
Aldawsari M, Alam A, Imran M
ACS Omega . 2024 Jul; 9(25):27300-27311. PMID: 38947795
This study conducts a systematic investigation of the creation and optimization of a rutin-loaded transethosome intended for topical use. The formulation's characteristics were thoroughly assessed for vesicle size (160.45 ±...
4.
Alzhrani R, Almalki A, Alosaimi M, Algarni M, Abduljabbar M, Aldawsari M, et al.
Spectrochim Acta A Mol Biomol Spectrosc . 2024 Jun; 320:124543. PMID: 38850821
Futibatinib is a powerful inhibitor of fibroblast growth factor receptors that impedes its phosphorylation and subsequently leading to a reduction in in cell viability across various cell lines. Futibatinib was...
5.
Alzhrani R, Aldawsari M, Alamoudi J
Front Med (Lausanne) . 2024 Jun; 11:1397648. PMID: 38841581
For cancer therapy, the focus is now on targeting the chemotherapy drugs to cancer cells without damaging other normal cells. The new materials based on bio-compatible magnetic carriers would be...
6.
Almutairy B, Khafagy E, Aldawsari M, Alshetaili A, Alotaibi H, Lila A
ACS Omega . 2024 May; 9(17):19536-19547. PMID: 38708263
Pediatric pulmonary hypertension is a serious syndrome with significant morbidity and mortality. Sildenafil is widely used off-label in pediatric patients with pulmonary arterial hypertension. In this study, bile salt-stabilized nanovesicles...
7.
Mujtaba M, Kaleem M, Chaware R, Ingole A, Asiri Y, Hassan M, et al.
ACS Omega . 2024 Apr; 9(14):16346-16357. PMID: 38617636
This research work aimed to develop and evaluate proniosomes for the oral delivery of the lipophilic drug Irbesartan (IRB) to improve its solubility and bioavailability. Proniosomes of Irbesartan were formulated...
8.
Almutairy B, Khafagy E, Aldawsari M, Alshetaili A, Alotaibi H, Lila A
Int J Pharm X . 2024 Apr; 7:100240. PMID: 38577618
Bimatoprost (BIM) is a prostaglandin F2α analogs originally approved for the treatment of glaucoma and ocular hypertension. Recent studies have highlighted its potential to boost hair growth. The objective of...
9.
Mahajan N, Mujtaba M, Fule R, Thakre S, Akhtar M, Alavudeen S, et al.
ACS Omega . 2024 Feb; 9(7):8139-8150. PMID: 38405505
Tenofovir (TNF) is a common component of many antiretroviral therapy regimens, but it is associated with poor membrane permeability and low oral bioavailability. To improve its oral bioavailability and membrane...
10.
Aldawsari M, Kamal M, Balaha M, Jawaid T, Jafar M, Hashmi S, et al.
Saudi Pharm J . 2024 Feb; 32(3):101984. PMID: 38384476
Current research focuses on explicitly developing and evaluating nanostructured lipidic carriers (NLCs) for the chemotherapeutic drug Ribociclib (RCB) via the topical route to surmount the inherent bioavailability shortcomings. The absolute...